invivodata: FDA’s New PRO Guidance Highlights Patient’s Perspective

Bio-IT World (May 18 2010) Pharmaceuticals

1. eCliniqua | Evidence is mounting that the Food and Drug Administration (FDA) wants to hear the voice of the patient in clinical trials. "They want to make sure PRO data are collected in a reliable way so they can make reasonable judgments based on those data,” says Doug Engfer, president and CEO of invivodata. (Read Full Article)

   Bookmark or Share this article

Login to comment.